Novavax Vaccine in 'Good Shape' for Approval Filing: CEO

The video discusses the progress and challenges in manufacturing a vaccine, emphasizing that delays are due to manufacturing issues, not vaccine efficacy. It highlights the vaccine's high efficacy and safety profile, its stability at higher temperatures, and ongoing trials against various COVID-19 variants. The company is conducting booster trials and has shared its IP with global partners to ensure widespread distribution. Trials for children are also underway.

How does the company plan to address the issue of waning antibodies over time?

What is the company's approach to sharing intellectual property for vaccine distribution?

What trials are being conducted for children regarding the vaccine?